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achieved in 81.2% (13/16) of responders, and occurred a median 10
(2-34.7) months after ECP. Nine cases (56.2%) had recurrent
cGvHD at 8.4 (3-19.3) months after achieving response and 1
(6.25%) had late primary disease relapse (6 months after ECP
initiation). Another non-responder had a late relapse. Factors as-
sociated with OR were younger age at cGvHD diagnosis and at
ECP initiation (50 years, P0.046), while that with CR was early
initiation of ECP within 18 months of cGvHD diagnosis
(P0.018). The 1-year, 2-year and 3-year post ECP initiation
survival rates were 66.7%, 38.1% and 23.8%. Types of cGvHD
onset and donor were associated with survival post ECP initiation
(P0.028 and P0.05). The patients with non-progressive onset
cGvHD and with HLA-MRD survived longer (1-year post ECP
initiation survival rates of 88.9% and 78.6%) than those with
progressive onset cGvHD and with HLA-MUD (50% and 33.3%).
However, OR and CR to ECP were not associated with prolonged
post ECP initiation survival. In summary, our results suggest that
ECP is an effective second-line treatment option for cGvHD
especially with early initiation. Progressive onset cGvHD and
HLA-MUD were associated with poor survival rates in patients
receiving ECP for cGvHD. Whether response to ECP would be
translated to higher survival requires a larger study.
Table
Characteristics Details
Sex: male/female (n/n) 9/12
Median age (median, range)
-- At day 0 42.6 (26.5-60.1) years
-- At cGvHD diagnosis 42.8 (26.8-60.4) years
-- At ECP initiation 43.4 (28-60.4) years
Type: HLA-MRD/-MUD/-
mismatched unrelated CBD
(n) 14/6/1
GvHD Prophylaxis (n)
-- Calcineurin inhibitor and
methotrexate 18
-- Calcineurin inhibitor and
methylprednisolone 2
-- Triple regimen 1
Acute GvHD (n) 19
-- Clinical Grade: I/II/III/IV 5/12/1/1
-- ECP for aGvHD 1
Chronic GvHD (n) 21
-- Onset: De novo/Progressive/
Recurrent (n) 1/13/7
-- CIBMTR Overall
Severity at ECP
initiation (n)
........Mild 2
........Moderate 11
........Severe 8
-- Maximum Grade (n)
........Limited 3
........Extensive 18
-- Median duration of ECP
(median, range)
10.8 (1.3-58.8)
months
-- Median follow-up time
after ECP initiation
(median,range)
15.5 (1.3-62.4)
months
-- Overall and complete
response to ECP by
CIBMTR Severity
........Mild (n (%)) 1 (50%), 1 (50%)
........Moderate (n (%)) 5 (45.4%), 4 (36.4%)
........Severe (n (%)) 5 (62.5%), 3 (37.5%)
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INTERACTION BETWEEN HOST NATURAL KILLER T CELLS AND DONOR
CD4CD25 TREG CELLS PROTECTS AGAINST GVHD AFTER TLI/ATS
HOST CONDITIONING AND ALLOGENEIC BONE MARROW TRANSPLAN-
TATION
Pillai, A.B.1, Dutt, S.1, George, T.I.1, Strober, S.A.1 1Stanford Uni-
versity School of Medicine, Stanford, CA.
The murine non-myeloablative regimen of total lymphoid irra-
diation (TLI) and anti-thymocyte serum (ATS) prevents acute
graft-versus host disease (aGVHD) and was recently successfully
applied for human hematolymphoid malignancies (Lowsky et al,
NEJM, 2005). To investigate GVHD protection, we transplanted
(BMT) 50 106 bone marrow cells and 60 106 splenocytes from
wild-type (WT), CD4-/-, IL-4-/-, or IL-10-/- C57BL/6 (H-2b) do-
nor mice into wild-type (WT) or natural killer (NK) T cell deﬁ-
cient J
18-/- BALB/c (H-2d) hosts following TLI/ATS. Controls
were WT BALB/c mice given 800cGy total body irradiation (TBI)
and ATS with BMT from WT C57BL/6 donors. TBI/ATS-con-
ditioned WT hosts given BMT from WT donors and TLI/ATS
conditioned WT hosts given BMT from CD4-/-, IL-4-/-, or IL-
10-/- donors developed aGVHD, with marked donor CD8 T cell
accumulation in liver, mesenteric lymph nodes (MLN), and colon
at day 6. Since GVHD protection depends on donor CD4 cells,
IL-4, and IL-10, we investigated the role of donor CD4 Tregs in
GVHD protection. TLI/ATS-conditioned WT hosts given BMT
from WT donors survived without aGVHD and demonstrated a
dramatic (p 0.01) ten-fold increase in the absolute number of
donor CD4CD25Foxp3Tregs in the spleen at day 6 after BMT
relative to TBI/ATS-conditioned WT hosts or TLI/ATS-condi-
tioned J
18-/- hosts that succumbed to aGVHD. These
CD4CD25Foxp3 Tregs secreted IL-4 and IL-10 and had the
GVHD suppression capacity of conventional CD4CD25 Tregs.
Pre-transplant adoptive transfer of sorted WT host invariant NK
T cells protected TLI/ATS-conditioned J
18-/- hosts from day 6
donor CD8 T cell accumulation and caused a signiﬁcant
(p  0.01) increase in the absolute number of donor
CD4CD25Foxp3 Tregs. Using congenic markers (CD45.1/
CD45.2), we found that these CD4Tregs arise from donor splenic
(peripheral) T cells after BMT. CD25 depletion of WT donor cells
before BMT into TLI/ATS-conditioned WT hosts or into TLI/
ATS-conditioned J
18-/- hosts given adoptive transfer of WT host
NK T cells resulted in loss of the donor CD4CD25Foxp3
Tregs subsets in the spleen, and signiﬁcantly increased day 6 donor
CD8 T cell accumulation in the host liver, MLN, and colon,
accompanied by lethal aGVHD. These studies show that host
invariant NK T cells are critical for GVHD protection and that
they can facilitate the expansion of donor CD4CD25Foxp3
Tregs, which protect TLI/ATS treated hosts from lethal GVHD
after allogeneic BMT.
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IN VIVO ACTIVATION OF APCS WITH TLR LIGANDS AND TISSUE DAM-
AGE RATHER THAN AMOUNT OF HOST APCS ARE CRITICAL FACTORS
THAT DETERMINE DLI-MEDIATED GVL REACTIVITY AND GVHD IN
MHC-MATCHED MINOR HISTOCOMPATIBILITY ANTIGEN (MHAG)-MIS-
MATCHED CHIMERAS
Radojcic, V.1, Skarica, M.1, Murphy, G.F.2, Luznik, L.1 1Division of
Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Cen-
ter at Johns Hopkins, Baltimore, MD; 2Department of Pathology,
Brigham and Women’s Hospital and Harvard Medical School, Boston,
MA.
We recently found that residual host CD11c DCs persist in the
skin of MHC-matched chimeras after myeloablative conditioning
and transplantation of T cell-repleted BM, and that those residual
host APCs are insufﬁcient for the induction of optimal DLI-
mediated alloreactivity (J Immunol.,2006). Since the latter obser-
vation in established C3H.SW3B6 chimeras differs from the
current paradigm in freshly irradiated MHC-matched chimeras,
we hypothesized that in established chimeras, beside host APCs
and donor T cells, the induction of DLI-mediated GVL reactivity
and GVHD requires two additional factors: (a) TLR-mediated
activation of APCs and (b) tissue damage. In vivo coadministration
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